Simcere Pharmaceutical is paying Connect Biopharma $21 million upfront and offering up to $120 million in biobucks for the right to develop and commercialize Connect’s monoclonal antibody (mAb) to treat certain inflammatory diseases in Greater China.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Simcere Pharmaceutical Group Limited (2096.HK) (Simcere) announced a Sponsored Research Agreement with Mass General Brigham. With more than 80,000 employees, 13 Nobel laureates and an annual research budget of $2 billion, Mass General Brigham is one of the largest and most prestigious academic medical centers in the United States. Under the agreement up to eight research groups at Mass General Brigham will be funded on select projects over the course of two years.
NANJING, China, March 14, 2023 /PRNewswire/ -- Simcere Pharmaceutical Group Limited (2096.HK) (Simcere), an innovative global biopharmaceutical company, announced today that Simcere Zaiming, an innovative oncology pharmaceutical company of Simcere has entered into a clinical collaboration agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA) to evaluate the combination of SIM0235, a potential first-in-class humanized anti-tumor necrosis factor receptor 2 (TNFR2) monoclonal antibody, and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors and cutaneous T-cell lymphoma (CTCL).
BEIJING, Jan 29 (Reuters) - China has approved two domestically developed oral medicines for COVID-19 patients with mild symptoms, the National Medical Products Administration said on Sunday.
For a modest upfront of $30 million, Simcere is buying regional rights for daridorexant, Idorsia’s insomnia drug that’s marketed as Quviviq in the US and Europe. Simcere will get the rights in China, Hong Kong and Macau.